Lithium batteries have taken over as the primary battery chemistry from applications ranging from consumer electronics to ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership for ...

SHENZHEN, GUANGDONG, CHINA, January 7, 2026 /EINPresswire.com/ -- Performance and safety of advanced energy storage ...

LiFePO4 adoption is becoming a necessity in the industry, not just a preference. It is a strategic requirement for many critical applications. The rechargeable battery market was dominated for decades ...

BMS is focusing on a diversified portfolio to stabilize and grow revenues post-loss-of-exclusivity, avoiding reliance on a single blockbuster. Pipeline execution in oncology, cardiovascular, and ...